To evaluate the feasibility of using the pressure support ventilation with volume guarantee (PSV-VG) as an initial ventilatory mode in preterm infants with respiratory distress syndrome (RDS) after surfactant treatment to achieve accelerated weaning of peak inspiratory pressure (PIP) and mean airway pressure (MAP).
INTRODUCTION
Premature newborns with respiratory distress syndrome (RDS) are commonly managed with ventilators employing a pressure-limited mode. In such pressure-limited ventilation modes, tidal volumes (V T ) delivered by the ventilator can be quite variable due to changes in patient's pulmonary mechanics. In premature infants with RDS, surfactant treatment dramatically increases functional residual capacity (FRC) and pulmonary compliance. [1] [2] [3] If ventilator settings are not weaned rapidly, the patient may undergo traumatic lung injury 4, 5 or even ischemic brain injury secondary to hyperventilation. 6 Recently, several new modalities have been introduced to address the theoretical deficiencies of a pressure-limited ventilation mode. 7, 8 Draeger Babylog 8000 plus ventilators include a number of modifications of time-cycled, pressure-limited ventilation (designed to target a set tidal volume by microprocessor-directed adjustments of peak inspiratory pressure (PIP) or inspiratory time (IT) . They have a ''volume guarantee'' option (VG), which allows them to deliver a desired V T during inspiration with a minimum possible inspiratory pressure. This is performed with a breath-to-breath determination of the baby's dynamic compliance, resistance and patient effort, using exhaled V T measurements. Pressure support ventilation (PSV) synchronizes the beginning of inspiration and terminates each breath when inspiratory flow declines to a preset threshold, thereby eliminating inspiratory hold and synchronizing expiration with the onset of the infant's own expiration. 9 A combination of these two capabilities, pressure support ventilation with VG (PSV-VG), hypothetically should reduce ventilator-inflicted damage to the lungs of premature babies by synchronizing machine inspirations with the baby's inspiratory efforts, allowing the baby to control the duration of inspiration, and limiting the pressure required to achieve the desired V T . In this pilot study, we hypothesized that PSV-VG would result in accelerated weaning of ventilatory parameters such as PIP and mean airway pressure (MAP) in premature infants with RDS after they have been treated with surfactant.
METHODS
This pilot study was performed in the neonatal intensive care unit (NICU) of the Mount Sinai Medical Center, New York, after approval by the Institutional Review Board. Ventilated preterm neonates with birth weights of r1500 g, with a clinical and radiographic diagnosis of RDS within the first 12 hours of life and who were about to receive surfactant (Survanta R , Ross Laboratories) were recruited into the study after informed consent from parents had been obtained. Babies with major congenital malformations, congenital heart disease, confirmed or suspected sepsis/pneumonia, pneumothoraces or other forms of air leak on admission, infants requiring paralysis or heavy sedation, or babies in a terminal state on admission were excluded. The primary outcome variables in this study were ventilatory pressures during the first 24 hours after surfactant administration or randomization.
Once the criteria for entry into the study were met, subjects were enrolled in this prospective, randomized controlled pilot study through the selection from separate weight-specific packs of sealed envelopes, divided evenly between PSV-VG mode and the synchronized intermittent mandatory ventilation (SIMV). This was performed at the time of administration of the first dose of surfactant. Block randomization was performed with stratification by weight; the categories were 500 to 750, 751 to 1000, 1001 to 1250, and 1251 to 1500 g. Formal sample size power analysis was not carried out, because data on variability were not available. The investigators felt that a trial of 40 patients would be sufficient for a pilot project to get base-line data. Since the neonatal unit at Mount Sinai Medical Center started using more of nasal continuous positive airway pressure (NCPAP), the recruitment for this trial became difficult. Therefore, the trial was stopped after only 34 patients.
After assignment to a group, the baby was placed on the chosen mode of ventilation, and the ventilator parameters (PIP, positive end expiratory pressure [PEEP] , IT , and rate in the SIMV group; maximum pressure, PEEP, maximum IT (0.5 seconds), and target V T 5 ml/kg in the PSV-VG group) were adjusted to give targeted arterial blood gases of pH 7.25 to 7.35, PaCO 2 45 to 55 mmHg, and PaO 2 50 to 70 mmHg. The SIMV ventilator was set up without using the calculated tidal volume. All babies in the study were ventilated with the Babylog 8000 plus (Dräger Medical Inc., Telford, PA). Infants were studied for a total of 24 hours. The ventilator setting right before the surfactant administration was artificially defined as time point 0. During the study period, we maintained targeting blood gases and weaned the patients in the SIMV group by altering FiO 2, PIP, and rate, and patients in the PSV-VG group by altering FiO 2 as well as V T once measured PIP was less than 16 cm H 2 O. The parameters were watched carefully for consistency before weaning of V T was undertaken. All patients were monitored continuously for heart rate, blood pressure, and pulse oximetry (to keep O 2 saturation between 88 and 95%). Blood gases and ventilator data were recorded on a respiratory sheet designed for this study. The data were averaged over a 6-hour period. The oxygenation index (OI) was calculated as the mean airway pressure Â percent-inspired oxygen divided by the arterial PaO 2 . Subsequent doses of intratracheal surfactant were administered 8 to 12 hours after the first dose, if the oxygen requirements were higher than 35%. After 24 hours, attending neonatologists provided ventilation management and other care as indicated clinically.
The survival at the time of discharge, the incidence of chronic lung disease (CLD), defined as O 2 requirement and/or CPAP at 36 weeks postmenstrual age, the occurrence of intraventricular hemorrhage (IVH), patent ductus arteriosus (PDA) requiring indomethacin or ligation, necrotizing enterocolitis (NEC) defined as Bell stage 2 or greater, air dissection (either pulmonary interstitial emphysema, pneumothorax, or pneumomediastinum), and retinopathy of prematurity (ROP) were recorded from the medical charts.
Statistics were performed using SPSS for Windows version 12 (SPSS Inc., Chicago, IL) and StatXact version 6 (Cytel Software Corporation, Cambridge, MA). Unpaired data were compared with the Fisher's exact test for dichotomous variables and the Student's t-test or the Mann-Whitney test for continuous variables, as appropriate. Evolution of variables over time was assessed using repeated measures analysis of variance (ANOVA) for continuous variables. If assumptions of normality and homogeneity of variance were not met, we used repeated measures ANOVA by ranks (Puri and Sen's L statistics treated as a w 2 approximation, and calculated by multiplying Pillai's Trace by the degree of freedom). 10 A p-value less than 0.05 was considered significant. Values are presented as mean±SEM if normally distributed (as assessed by normal probability plot and Kolmogorov-Smirnov test), and as median with quartiles, ranges, or box-plots otherwise. The numbers of surfactant doses were compared using a singly ordered RXC table (Kruskall-Wallis test with exact calculation of probability).
RESULTS
In all, 34 patients were recruited into the study. A total of 16 were randomized to the PSV-VG group and 18 to the SIMV group. As is shown in Table 1 , the groups did not differ significantly in birth weight, gestational age, sex ratio, delivery mode, prenatal medications, and Apgar scores. Furthermore, as is presented in Table 2 , the groups were not significantly different in initial arterial blood gases, ventilator settings, inspired oxygen concentrations, and oxygenation indices. Among the SIMV patients, eight received one surfactant dose, nine received two doses, and one received three doses; among the PSV-VG patients, six received one surfactant dose, seven received two doses, and three babies received three doses ( p ¼ 0.580, Kruskal-Wallis test). The median numbers (ranges in parentheses) of blood gases during the first 24 hours were 4 (3 to 6) and 3 (2 to 4) in SIMV and PSV-VG groups, respectively (U ¼ 42, p<0.001).
The changes in PIP and MAP of the two groups at 0 (presurfactant) and 6, 12, 18, and 24 hours after surfactant administration are shown in the Figures 1 and 2 . PIP and MAP decreased over time ( p<0.001) during the first 24 hours after surfactant administration in both groups but the decrease in MAP was faster in the SIMV group compared to the PSV-VG group ( p ¼ 0.035).
As is indicated in Table 3 , there were no significant differences in the important clinical outcome variables. The incidences of CLD, death, and their combination were not significantly different in the two groups. As is indicated in Table 4 , there were no statistically significant differences in any of the other outcome variables examined. Thus, the incidences of air dissection, cerebral hemorrhage, ROP, failed hearing screen, PDA requiring intervention, or NEC were not significantly different between the two groups.
DISCUSSION
Pressure-limited ventilation modes such as SIMV are routinely used in the management of neonates with respiratory failure as a result of its ease of use and safety. 11 The ventilator parameters are set by the physician and do not change from breath to breath, regardless of changes in the baby's ventilatory mechanics. There may be disadvantages to ventilating babies in the pressure-limited ventilation modes due to dynamically changing patient FRC, compliance, resistance, respiratory rate, and effort resulting in inconsistent volume delivery, particularly after surfactant administration. [1] [2] [3] Furthermore, since IT is fixed in the SIMV mode, asynchrony of machine and patient expiratory phases theoretically could lead to increased work of breathing and volutrauma. Given the importance of avoiding ventilator-induced trauma and neurotoxicity, faster weaning would be highly desirable.
Recently, volume-targeted ventilation has been proposed to achieve faster weaning, and autoregulation of inspiratory pressure makes VG a self-weaning mode with a potential to minimize blood gas analyses. However, at this point of time, only greater stability of delivered V T , decreased PIP, and less hypocarbia have been demonstrated in short-term studies of the VG mode of the Draeger baby log.
9,12 -14 Olsen et al. 15 compared SIMV with PSV-VG during the acute phase of RDS after surfactant administration, with each baby serving as its own control. They concluded that there was no advantage to PSV-VG.
In this present trial, over the 24 hours of study period, weaning of PIP and MAP was achieved in both groups over time but, in fact, it was demonstrated by repeated measures ANOVA by rank that the slope of decrease in MAP was steeper in the SIMV group. The initial MAP was slightly but not significantly higher in PSV-VG group. A sensitivity analysis excluding the three outliers in the SIMV group yielded the same findings. These data suggest that it may be possible to achieve faster weaning in the SIMV mode by aggressive weaning practices than in PSV-VG by microprocessor-assisted weaning. However, PSV-VG achieved weaning utilizing a fewer number of blood gases compared to the SIMV group in which the weaning was performed manually based on the blood gases analyzed. Nevertheless, time to extubation and incidence of CLD was similar in both groups. Therefore, the concept of faster weaning did not translate into any long-term benefits. Other outcome variables such as rate of air dissection, NEC, PDA, failed brain stem auditory-evoked response, ROP, and the incidence of major IVH were not statistically different between the two groups. Thus, despite the very strong intuitive appeal to neonatologists of using newer modes of ventilation, assiduous attention to details may allow caretakers to achieve the same results without resort to newer microprocessor-controlled ventilators. Limitations of this study include lack of sample size analysis, small sample size, inability to blind, and subjectivity in how ventilators were set up and managed. It is possible that sample size may have been too small to detect a true difference in outcome. We were unable to calculate the observed power for the primary outcomes (PIP and MAP), because no sample size method is available for the nonparametric repeated measures ANOVA used in this study. However, we were able to calculate the observed power to detect a significant change in the frequency of CLD. This study had an observed power of only 0.104 to detect a significant 40% change in the frequency of CLD among all infants using a two-tailed w 2 analysis and an alpha error of 0.05. We would have needed 279 patients in each group to detect a 40% decrease in the risk of CLD among all infants with a power of 0.8.
In summary, in this pilot study, PSV-VG did not achieve accelerated weaning or affect any of the important clinical outcomes when used as the initial ventilatory mode in surfactanttreated premature newborns with RDS. Nevertheless, this mode may be useful in minimizing the frequency of arterial blood sampling in very immature infants.
